All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 2 April 2019, Mark Geyer and colleagues from the Memorial Sloan Kettering Cancer Center, New York, NY, USA, published in JCI Insight the results of a phase I trial. This study investigated the safety and long-term follow-up of chimeric antigen receptor T-cell (CAR-T) therapy with or without conditioning chemotherapy in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (B-NHL).
CAR-T therapy has shown great promise for the treatment of patients with R/R CLL or B-cell NHL who cannot be cured with standard of care regimens and who constitute a great unmet medical need. In this single-center, non-blinded, phase I trial (NCT00466531), the investigators sought to evaluate the efficacy and toxicity their CAR-T construct with or without conditioning chemotherapy.
|
CLL cohort |
B-NHL cohort |
---|---|---|
Median follow-up (range) |
40.6 (1.8−79.8) months |
- |
Median event-free survival |
3.1 months |
33.4 months |
Median overall survival |
17.1 months |
Not reached |
Objective response |
38% |
- |
Complete response (CR) by IWCLL or Lugano criteria, respectively |
n = 3/12 |
n = 2 |
Stable disease by IWCLL or Lugano criteria, respectively |
n = 9 |
n = 2 |
Patients remaining in CR at median follow-up of 53 months or 24.7 months, respectively |
100% (3/3) |
50% |
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox